MRI (magnetic resonance imaging) imaging agent gains NCI (US National Cancer Institute) support:
This article was originally published in Clinica
Executive Summary
Targesome has received support from the US National Cancer Institute (NCI) to further its development of an MRI-based molecular imaging agent that can help detect cancer and metastatic disease. The Palo Alto, California company is investigating the use of its proprietary nanoparticles that target new blood vessel formation, a process essential for tumour growth and metastases. The technique involves the use of a human monoclonal antibody which is attached to Targesome's injectable nanoparticles labelled with gadolinium ions and which binds to a specific endothelial marker.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.